The Drug Regulatory Authority of Pakistan (DRAP) has imposed a ban on eight batches of counterfeit and substandard medicines used for diabetes and life-saving treatments, citing concerns over their quality, efficacy, and potential impact on patient care.
According to reports, DRAP is conducting a crackdown across Punjab, Balochistan, and Khyber Pakhtunkhwa, where it identified and seized counterfeit and substandard medicines.
RecommendedMust Read
The Central Drug Testing Lab in Karachi declared eight batches of these medicines as substandard. The banned batches include: Diabetes Tablet: Amplemet XR (Batch 39224), Antibiotic Injection: Esanix (Batch IA702), Drip Solution: Zesol Drip (Batch 2408207), Sterile Water for Injection: (Batch WI893), Bacterial Infection Medicine: Flagenis Suspension (Batch 0362), Anti-Allergy Syrup: Desora Syrup (Batch S23236) and Vitamin B12 Infusions: Cyanoco Infusion (Batch 6609) and Cyanoco Super (Batch 6403).
The medicines in question were produced by companies in Karachi, Lahore, Faisalabad, and Haripur. Investigations revealed that these drugs had unclear efficacy and posed risks to patient treatment.
